- Home
- KNSA vs ELVN Comparison
KNSA vs ELVN Comparison
Compare KNSA & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNSA | ELVN |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.2B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KNSA | ELVN |
|---|---|---|
| Price | $79.55 | $41.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $98.00 | $73.67 |
| AVG Volume (30 Days) | 408.7K | ★ 1.2M |
| Earning Date | 10-27-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 225.00 | 3.17 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $677,564,000.00 | N/A |
| Revenue This Year | $46.66 | N/A |
| Revenue Next Year | $22.90 | N/A |
| P/E Ratio | $291.67 | ★ N/A |
| Revenue Growth | ★ 60.09 | N/A |
| 52 Week Low | $35.53 | $14.79 |
| 52 Week High | $82.94 | $62.32 |
Technical Indicators
Market Signals| Indicator | KNSA | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 60.46 | 25.15 |
| Support Level | $73.81 | $38.58 |
| Resistance Level | $81.42 | $43.05 |
| Average True Range (ATR) | 2.60 | 1.88 |
| MACD | 0.30 | -0.38 |
| Stochastic Oscillator | 86.28 | 20.85 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.